See more : La Française des Jeux Société anonyme (LFDJF) Income Statement Analysis – Financial Results
Complete financial analysis of Global Cord Blood Corporation (CO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Global Cord Blood Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Global Quest Ltd. (GLBB) Income Statement Analysis – Financial Results
- Flowery Gold Mines Co. (FLOD) Income Statement Analysis – Financial Results
- My Rewards International Limited (MRI.AX) Income Statement Analysis – Financial Results
- Anyuan Coal Industry Group Co., Ltd. (600397.SS) Income Statement Analysis – Financial Results
- Sierra Lake Acquisition Corp. (SIER) Income Statement Analysis – Financial Results
Global Cord Blood Corporation (CO)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.globalcordbloodcorp.com
About Global Cord Blood Corporation
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24B | 1.16B | 1.22B | 986.75M | 936.77M | 759.98M | 663.00M | 635.12M | 572.86M | 526.12M | 380.49M | 339.53M | 261.54M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 183.31M | 178.95M | 189.13M | 186.03M | 181.48M | 142.64M | 144.60M | 130.61M | 106.23M | 106.62M | 86.66M | 77.38M | 65.73M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.06B | 980.69M | 1.03B | 800.73M | 755.29M | 617.34M | 518.40M | 504.51M | 466.63M | 419.50M | 293.83M | 262.16M | 195.81M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 85.26% | 84.57% | 84.52% | 81.15% | 80.63% | 81.23% | 78.19% | 79.44% | 81.46% | 79.73% | 77.22% | 77.21% | 74.87% | 0.00% | 0.00% | 0.00% |
| Research & Development | 22.30M | 23.77M | 21.11M | 14.69M | 12.72M | 10.37M | 8.96M | 9.91M | 9.77M | 8.46M | 7.62M | 6.96M | 5.82M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 187.06M | 174.36M | 190.23M | 169.32M | 243.50M | 189.94M | 169.95M | 131.68M | 112.24M | 108.05M | 89.70M | 83.79M | 53.32M | 11.20M | 0.00 | 0.00 |
| Selling & Marketing | 241.73M | 237.69M | 261.96M | 235.06M | 219.20M | 178.48M | 148.16M | 127.93M | 112.69M | 93.68M | 61.68M | 47.58M | 39.48M | 0.00 | 0.00 | 0.00 |
| SG&A | 428.79M | 412.05M | 452.19M | 404.38M | 462.70M | 368.42M | 318.11M | 259.61M | 224.93M | 201.73M | 151.37M | 131.38M | 92.80M | 11.20M | 4.01M | 66.28K |
| Other Expenses | 6.27M | 8.16M | 7.39M | 5.70M | 4.23M | 5.97M | -113.00K | 861.00K | 2.21M | 203.00K | 0.00 | 0.00 | 0.00 | 594.98K | 220.52K | 166.41K |
| Operating Expenses | 451.08M | 435.82M | 473.30M | 419.07M | 475.42M | 352.47M | 327.07M | 269.52M | 234.71M | 210.19M | 158.99M | 138.34M | 98.61M | 11.80M | 4.23M | 232.69K |
| Cost & Expenses | 634.39M | 614.77M | 662.43M | 605.10M | 656.91M | 495.11M | 471.67M | 400.13M | 340.93M | 316.81M | 245.65M | 215.71M | 164.34M | 11.80M | 4.23M | 232.69K |
| Interest Income | 32.61M | 30.90M | 25.36M | 25.32M | 21.94M | 17.42M | 18.22M | 18.25M | 16.87M | 15.06M | 13.43M | 9.07M | 6.41M | 4.11M | 0.00 | 250.79K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 3.26M | 119.42M | 107.97M | 101.10M | 70.08M | 70.10M | 3.29M | 2.61M | 2.43M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 19.91M | -26.82M | 12.97M | 52.37M | 50.59M | 50.48M | 50.17M | 50.61M | 37.07M | 35.87M | 29.36M | 23.48M | 20.43M | 3.92M | 7.10M | 250.79K |
| EBITDA | 628.78M | 518.05M | 572.00M | 404.75M | 353.60M | 333.71M | 299.10M | 306.33M | 297.44M | 256.96M | 174.26M | 151.71M | 96.81M | -7.88M | 2.87M | 18.11K |
| EBITDA Ratio | 50.58% | 44.67% | 46.83% | 41.02% | 37.75% | 43.91% | 45.11% | 48.23% | 51.92% | 48.84% | 45.80% | 44.68% | 37.02% | 0.00% | 0.00% | 0.00% |
| Operating Income | 608.87M | 544.87M | 559.03M | 381.66M | 279.86M | 264.87M | 191.33M | 235.00M | 231.93M | 209.31M | 134.84M | 123.82M | 97.19M | -11.80M | -4.23M | -232.69K |
| Operating Income Ratio | 48.97% | 46.99% | 45.77% | 38.68% | 29.88% | 34.85% | 28.86% | 37.00% | 40.49% | 39.78% | 35.44% | 36.47% | 37.16% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 18.97M | 65.88M | 19.78M | -25.20M | 23.67M | -98.55M | -50.00M | -79.88M | -41.00M | -51.13M | 16.76M | 8.32M | -17.53M | 3.92M | 7.10M | 250.79K |
| Income Before Tax | 627.84M | 610.75M | 578.81M | 356.46M | 303.54M | 166.31M | 141.33M | 155.12M | 190.92M | 158.19M | 151.60M | 132.14M | 79.66M | -7.88M | 2.87M | 18.11K |
| Income Before Tax Ratio | 50.50% | 52.67% | 47.39% | 36.12% | 32.40% | 21.88% | 21.32% | 24.42% | 33.33% | 30.07% | 39.84% | 38.92% | 30.46% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 118.35M | 94.55M | 101.08M | 61.26M | 62.66M | 37.62M | 50.00M | 47.33M | 58.40M | 38.54M | 9.63M | 33.93M | 24.77M | -4.11M | -7.47M | -18.11K |
| Net Income | 501.07M | 508.25M | 470.72M | 291.12M | 237.10M | 126.19M | 90.97M | 107.29M | 131.90M | 112.45M | 131.98M | 91.70M | 49.18M | -7.88M | 2.87M | 18.11K |
| Net Income Ratio | 40.30% | 43.83% | 38.54% | 29.50% | 25.31% | 16.60% | 13.72% | 16.89% | 23.03% | 21.37% | 34.69% | 27.01% | 18.80% | 0.00% | 0.00% | 0.00% |
| EPS | 4.12 | 4.18 | 3.87 | 2.40 | 1.99 | 1.59 | 1.25 | 1.36 | 1.60 | 1.49 | 1.79 | 1.31 | 0.69 | -1.13 | 0.41 | 0.01 |
| EPS Diluted | 4.12 | 4.18 | 3.87 | 2.40 | 1.99 | 1.59 | 1.25 | 1.36 | 1.60 | 1.49 | 1.79 | 1.31 | 0.66 | -1.13 | 0.41 | 0.01 |
| Weighted Avg Shares Out | 121.55M | 121.55M | 121.55M | 121.30M | 119.14M | 79.36M | 72.78M | 78.89M | 82.44M | 75.47M | 73.73M | 70.00M | 71.27M | 7.00M | 7.00M | 1.49M |
| Weighted Avg Shares Out (Dil) | 121.55M | 121.55M | 121.55M | 121.30M | 119.14M | 79.36M | 72.78M | 78.89M | 82.44M | 75.47M | 73.73M | 70.00M | 74.51M | 7.00M | 7.00M | 1.49M |
Global Cord Blood Corporation Investors: Looming Deadline in Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CO, CORBF
NEW YORK , June 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) between June 4, 2019 and May 3, 2022, both dates...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CO, CORBF
NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) between June 4, 2019 and May 3, 2022, both dates...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Global Cord Blood Corporation (CORBF)
LOS ANGELES, June 07, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 24, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or...
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Global Cord
NEW YORK , June 6, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Global Cord Blood Corporation ("Global Cord" or the "Company") (NYSE: CO, OTC: CORBF) and reminds investors of...
CORBF STOCKHOLDERS: Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Global Cord Blood Corporation Class Action
SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Global Cord Blood Corporation (OTC: CORBF) securities between June 4,...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Global Cord
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Global Cord Blood Corporation (“Global Cord” or the “Company”) (NYSE: CO, OTC: CORBF) and reminds investors of...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines – CORBF
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Global Cord Blood Corporation (“Global Cord” or the “Company”) (OTC: CORBF) and certain officers. The class action, filed in the...
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CO, CORBF
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) between June 4, 2019 and May 3, 2022, both...
Hach Rose Schirripa & Cheverie, LLP Announce Investigation Into Global Cord Blood Corp.
NEW YORK , June 3, 2024 /PRNewswire/ -- Hach Rose Schirripa & Cheverie, LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of law by certain officers and directors at Global Cord Blood Corporation (OTCPK:CORBF)...
Source: https://incomestatements.info
Category: Stock Reports